Maridebart Cafraglutide
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
Amgen · Phase 1 · Completed · Enrollment 349
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.